Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 465 participants.

Also called NCT02874794

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 465 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02874794
Other papers using this trial's data
  • Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial European journal of heart failure, 2022-07 DOI, PubMed 35560696, PMC12582518 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Changes in cardiac structure and function are associated with health-related quality of life in heart failure patients with reduced ejection fraction: Results from the EVALUATE-HF trial European journal of heart failure, 2025-11 DOI, PubMed 40678912
  • Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex Circulation. Heart failure, 2021-03 DOI, PubMed 33663237, PMC12611548 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02874794. Randomized; triple masking; primary purpose treatment. Start 2016-08-17 (actual); primary completion 2018-12-13 (actual). Results posted on 2020-03-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
Acronym
EVALUATE-HF
Condition
Heart Failure and Reduced Ejection Fraction
Intervention (Drug)
LCZ696 (sacubitril/valsartan)
Intervention (Drug)
Enalapril
Intervention (Drug)
Placebo of Enalapril
Intervention (Drug)
Placebo of LCZ696
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02874794
Content hash
00577625a1cac268f27f150208e5adfe0dd859ada9ac18e57e516d4b6f2811a3